Daraxonrasib Shows Early Activity in RAS-Mutated Pancreatic Cancer
This phase 1-2 study offers pharmacists the first substantial clinical safety and efficacy dataset for an oral pan-RAS(ON) inhibitor in previously treated RAS-mutated pancreatic cancer, a setting with historically dismal outcomes.
Daraxonrasib shows promise in advanced RAS-mutated pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, especially for tumors with RAS mutations, making new therapies critical. In patients with RAS-mutated PDAC, daraxonrasib showed a 35% objective response in a subgroup with RAS G12 mutations and an acceptable safety profile. While daraxonrasib demonstrates promising antitumor activity, the high incidence of adverse effects requires careful consideration in treatment planning. Daraxonrasib shows potential efficacy in RAS-mutated PDAC but leads to significant adverse effects.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.